Trials / Completed
CompletedNCT02088515
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is a second-generation platinum compound that is more active against squamous cell carcinoma of the lung with a response rate of 60%, issued by the finished Phase II trial in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nedaplatin | |
| DRUG | Cisplatin | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-10-01
- Completion
- 2017-02-01
- First posted
- 2014-03-17
- Last updated
- 2017-03-03
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02088515. Inclusion in this directory is not an endorsement.